Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of AdvisorShares Psychedelics ETF (ARCA:PSIL) through any online brokerage.
There are no as such competitors for AdvisorShares Psychedelics ETF.
There is no analysis for AdvisorShares Psychedelics ETF to provide a consensus price target.
The stock price for AdvisorShares Psychedelics ETF (ARCA: PSIL) is $ last updated .
There are no upcoming dividends for AdvisorShares Psychedelics ETF.
AdvisorShares Psychedelics ETF does not have any upcoming earnings scheduled.
There is no upcoming split for AdvisorShares Psychedelics ETF.
| Sector | Healthcare |
| Category | Mid Performer-Mid Growth |
| Investment Style | Large Cap Value |
| Fund Inception | Sep 15, 2021 |
| Managers | Dan S. Ahrens |
| Definition | Most of the stocks in this equity fund have average financial performance and average growth potential |
| Symbol | Name | Share % |
|---|---|---|
| CA | Definium Therapeutics,... | 11.9% |
| CMPS | Compass Pathways Plc A... | 9.70% |
| MU | Atai Life Sciences BV | 14.1% |
| RLMD | Relmada Therapeutics I... | 5.16% |
| GHRS | Gh Research Plc | 4.66% |
| ANRO | Alto Neuroscience, Inc... | 4.48% |
| NRXP | NRX Pharmaceuticals In... | 5.61% |
| NBIX | Neurocrine Biosciences... | 4.88% |
| ABBV | Abbvie Inc. | 4.53% |
Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API
Market data provided by Benzinga APIs
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
